Kusurinomadoguchi, Inc. (JP:5592)
:5592
Top Page
Kusurinomadoguchi, Inc.
(5592)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥2,544.00
▼(-4.40% Downside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by strong reported profitability and revenue growth, supported by reasonable valuation. These positives are tempered by a significant cash-flow deterioration (negative operating and free cash flow in 2025) and a technically weak price trend below key moving averages.
Positive Factors
Sustained Revenue Growth
Revenue nearly doubled over three years with acceleration in 2025, indicating durable demand for the company's offerings and expanding market penetration. Such multi-year top-line growth supports scale benefits, repeatable sales capacity, and long-term investment in product and sales capabilities.
Negative Factors
Severe Cash Flow Deterioration
Despite reported net income, operating and free cash flow turned deeply negative in 2025, indicating earnings are not converting to cash. This undermines sustainable funding for capex, dividends, or working capital and may force external financing or asset sales, weakening medium-term financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue nearly doubled over three years with acceleration in 2025, indicating durable demand for the company's offerings and expanding market penetration. Such multi-year top-line growth supports scale benefits, repeatable sales capacity, and long-term investment in product and sales capabilities.
Read all positive factors
Kusurinomadoguchi, Inc. (5592) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥28.68B
Dividend Yield1.03%
Average Volume (3M)73.92K
Price to Earnings (P/E)15.0
Beta (1Y)0.74
Revenue Growth16.86%
EPS Growth241.49%
CountryJP
Employees505
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)44.36
Shares Outstanding11,455,582
10 Day Avg. Volume72,500
30 Day Avg. Volume73,916
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.65
Price to Sales (P/S)2.00
P/FCF Ratio-4.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)206.9
Revenue Forecast (FY)N/A
Kusurinomadoguchi, Inc. Business Overview & Revenue Model
Company Description
Kusurinomadoguchi, Inc. provides solutions for pharmacies and medical care in Japan. The company offers EPARK drug counter, a pharmacy/drugstore search and reservation site; matching site to buy and sell dead stock medicines at dispensing pharmaci...
How the Company Makes Money
null...
Kusurinomadoguchi, Inc. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.48B | 11.20B | 8.72B | 7.42B | 6.49B |
| Gross Profit | 6.62B | 6.48B | 4.93B | 4.07B | 3.37B |
| EBITDA | 3.26B | 2.97B | 2.35B | 1.68B | 1.51B |
| Net Income | 2.18B | 2.03B | 870.92M | 391.45M | 515.61M |
Balance Sheet | |||||
| Total Assets | 11.87B | 12.16B | 23.07B | 12.22B | 11.02B |
| Cash, Cash Equivalents and Short-Term Investments | 1.89B | 2.15B | 14.59B | 5.95B | 5.02B |
| Total Debt | 56.01M | 72.47M | 5.42B | 137.49M | 149.56M |
| Total Liabilities | 3.25B | 3.64B | 16.65B | 9.43B | 8.06B |
| Stockholders Equity | 8.55B | 8.45B | 6.37B | 2.70B | 2.45B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -5.37B | 999.21M | 1.57B | 2.58B |
| Operating Cash Flow | 0.00 | -5.33B | 2.63B | 3.10B | 3.66B |
| Investing Cash Flow | 0.00 | -1.80B | -1.79B | -1.54B | -541.10M |
| Financing Cash Flow | 0.00 | -5.36B | 7.81B | -635.39M | -564.83M |
Kusurinomadoguchi, Inc. Technical Analysis
Negative
2661.00
Price Trends
2647.42
Negative
2707.39
Negative
3119.70
Negative
Market Momentum
-41.82
Positive
40.22
Neutral
7.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5592, the sentiment is Negative. The current price of 2661 is above the 20-day moving average (MA) of 2604.90, above the 50-day MA of 2647.42, and below the 200-day MA of 3119.70, indicating a bearish trend. The MACD of -41.82 indicates Positive momentum. The RSI at 40.22 is Neutral, neither overbought nor oversold. The STOCH value of 7.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:5592.
Kusurinomadoguchi, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ¥65.63B | 228.03 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥211.69B | 26.76 | ― | 0.43% | 20.55% | 48.62% | |
60 Neutral | ¥28.68B | 15.04 | ― | 1.03% | 16.86% | 241.49% | |
55 Neutral | ¥16.82B | -23.39 | ― | ― | 39.30% | 32.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥60.92B | 77.03 | 5.76% | ― | 31.95% | -40.95% | |
44 Neutral | ¥2.87B | -4.28 | ― | ― | 16.19% | -4.42% |
* Healthcare Sector Average
JP:5592
Kusurinomadoguchi, Inc.
2,504.00
640.77
34.39%
JP:4480
Medley
1,861.00
-1,239.00
-39.97%
JP:3902
Medical Data Vision Co.Ltd.
1,683.00
1,251.00
289.58%
JP:4263
SUSMED,Inc.
997.00
401.00
67.28%
JP:4438
Welby Inc.
347.00
-45.00
-11.48%
JP:4483
JMDC Inc.
3,235.00
366.55
12.78%
Kusurinomadoguchi, Inc. Corporate Events
Kusurinomadoguchi Details Q3 FY2026 Results Framework and Revenue Definitions
Feb 20, 2026
Kusurinomadoguchi, Inc. released a transcript of its financial results briefing for the third quarter of the fiscal year ending March 31, 2026, led by President and Representative Director Koji Tsutsumi. The company clarified definitions of its ke...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.